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Abstract: 3D cell cultures have emerged as a setting that resembles in vivo environments
replacing the traditional 2D. Over the recent years an extensive effort has been made
on the development of more physiologically relevant 3D cell culture platforms.
Extracellular matrix based materials have been reported as a bioactive and
biocompatible support for cell culture. For example, human plasma derivatives have
been extensively used as cell culture platforms. Despite all the promising results, in
most cases this type of materials have poor mechanical properties and stability in vitro.
Here we propose plasma based hydrogels with tunable mechanical properties and
increased stability. Platelet lysates were modified by addition of methacryloyl groups
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(PLMA) that polymerizes in controlled geometries upon UV-light exposure. The
hydrogels could also generate porous scaffolds after lyophilization. Our results showed
that PLMA materials own increased mechanical properties that can be adjustable by
changing PLMA concentration or modification degree. Cells readily adhere, proliferate
and migrate, exhibiting high viability when encapsulated in PLMA hydrogels.
The innovation potential of PLMA materials is based on the fact that is a complete
xeno-free solution for human cell culture, thus an effective alternative to the current
gold standards for 3D cell culture based on animal products.
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Three-dimensional (3D) cell culture platforms have emerged as a setting that resembles in vivo 21 
environments replacing the traditional 2-D cell culture systems. Over the recent years an 22 
extensive effort has been made on the development of more physiologically relevant 3D cell 23 
culture platforms.  24 
Extracellular matrix (ECM) based materials have been reported as a bioactive and 25 
biocompatible support for cell culture. For example, human plasma derivatives have been 26 
extensively used as cell culture platforms. Despite all the promising results, in most cases this 27 
type of materials have poor mechanical properties and poor stability in vitro. Here we propose 28 
plasma based hydrogels with tunable mechanical properties and increased stability. Platelet 29 
lysates were modified by addition of methacryloyl groups (PLMA) that polymerizes in 30 
controlled geometries upon UV light exposure. The hydrogels could also generate porous 31 
scaffolds after lyophilization. Our results showed that PLMA materials own increased 32 
mechanical properties that can be easily adjustable by changing PLMA concentration or 33 
modification degree. Cells readily adhere, proliferate and migrate, exhibiting high viability 34 
when encapsulated in PLMA hydrogels. 35 
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The innovation potential of PLMA materials is based on the fact that is a complete xeno-free 1 
solution for human cell culture, thus an effective alternative to the current gold standards for 2 
3D cell culture based on animal products. 3 
 4 
1.Introduction 5 
Culturing cells in two-dimensional (2D) substrates is still widely used for in vitro cell 6 
based assays. However, 2D platforms do not replicate the complex and dynamic in vivo cell 7 
microenvironment.[1,2] Three-dimensional (3D) cell culture systems have gained interest as they 8 
can better mimic the native extracellular matrix (ECM), its mechanical and biochemical signals 9 
and in vivo cell growth.[1–3] The 3D cell culture platforms have been applied in drug discovery, 10 
cancer cell biology, stem cell study, engineered functional tissues for implantation and other 11 
cell-based therapies.[2,4] 12 
In these shift from 2D to 3D cell culture, hydrogels have been emerging as one of the 13 
most promising 3D platforms. Hydrogels are soft 3D insoluble hydrophilic network systems 14 
with high water content, that allow for an easy transport of oxygen, nutrients and cell 15 
metabolites. Due to its similarities to the native ECM, both structural and compositional level, 16 
hydrogels have been adopted for 3D culture applications as they better mimic the physiological 17 
human context.[3,5–7] 18 
Currently, the gold standards for 3D cell culture for several cell types are collagen and 19 
the basement membrane proteins derived from the Engelbreth-Holm-Swarm (EHS) tumor.[8,9] 20 
Both matrices have shown to drive cellular self-organization and complex morphogenetic 21 
processes that resulted into sophisticated platforms for cell culture.[10] However, cell culture 22 
strategies using this type of materials goes against current animal-free approaches. Moreover, 23 
the mixture of proteins derived from the EHS tumor is a viscous material that quickly gelifies 24 
into very soft matrices, making it difficult to handle. As an alternative to animal-based gels, 25 
synthetic polymer-based gels have also been proposed to recreate native cell 26 
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microenvironments.[8] Despite the design flexibility for specific applications, such synthetic 1 
systems are typically expensive and their synthesis can be time consuming, requiring often 2 
multiple steps. Currently, striving toward personalized medicine and targeted therapy, creating 3 
the most appropriate material that closely mimics the in vivo microenvironment is one of the 4 
most important topics to address.  5 
Platelet concentrates (PC), obtained from whole blood by a differential centrifugation 6 
process, are an important source of growth factors (GFs), cytokines and other proteins.[11–13] 7 
Platelet lysates (PL) are derivatives obtained from PC by freeze/thaw cycles.[14,15] Previous 8 
works have reported the potential of PC based materials for cell culture.[16–18] Moreover, PC 9 
and PL have been used as an autologous material containing bioactive molecules, locally 10 
enhancing wound healing[19–21], bone growth and cartilage repair[22–25] and tissue healing[26]. 11 
Platelet-rich plasma (PRP) and PL based hydrogels have also been explored as 3D cell culture 12 
platforms and for tissue engineering (TE). Despite their great potential, a major disadvantage 13 
of these hydrogels is their poor mechanical properties and poor stability in vitro which hinders 14 
its application. The main goal in this study was the development of PL based hydrogels with 15 
increased mechanical properties and improved stability. Here we proposed the modification of 16 
PL by chemical conjugation with a photoresponsive group in order to achieve PL-based 17 
photopolymerizable materials with finely tunable mechanical properties. Such PL derived 18 
materials should provide a functional support for cell growth and interact with cells to control 19 
their function, guiding the process of tissue morphogenesis.  20 
We hypothesize that the herein proposed blood-derived materials that could have an 21 
allogenic origin, could be adequate to produce customized robust matrices rich in bioactive 22 
factors to be used as general platform for 3D cell cultures and in TE strategies in a more 23 
physiological setting. 24 
 25 
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2.Experimental Section 1 
2.1.Synthesis of methacryloyl platelet lysates (PLMA) 2 
PLMA were synthesized by reaction with methacrylic anhydride 94% (MA) (Sigma-3 
Aldrich, Germany). PL (STEMCELL Technologies, Canada) were thawed at 37ºC and to 10ml 4 
(total protein content 6.3g/dL) of this solution, either 100 or 300μL of MA was added, in order 5 
to synthesize PLMA100 (low modification degree) or PLMA300 (high modification degree) 6 
respectively. The reaction was performed under constant stirring at room temperature. The 7 
synthesized PLMA was then purified by dialysis with Float-A-Lyzer G2 Dialysis Device 3.5-5 8 
kDa (Spectrum, USA) against deionized water during 24h to remove the excess of MA. The 9 
PLMA solution was filtered with a 0.2 µm filter in order to sterilize it, frozen with liquid 10 
nitrogen, lyophilized and stored at 4ºC until further use. 11 
 12 
2.2.PLMA characterization 13 
2.2.1.1H NMR 14 
NMR analysis was used to verify the effective functionalization of original PL. 15 
Solutions of 10 mg/mL of non-modified PL and PLMA in methyl sulfoxide-d6 (DMSO) 99.5% 16 
(Fisher Scientific, USA) were prepared and analyzed by 1H-NMR with 18 seconds relaxation 17 
delay and 300 scans. The 1H NMR spectra were recorded on a Bruker AMX 300 spectrometer 18 
at 300.13 MHz. 19 
 20 
2.2.2.In-gel digestion and mass spectrometry analysis 21 
PL, PLMA100 and PLMA300 were separated in a 4–12% (w/v) acrylamide NuPAGE 22 
gradient pre-cast gel (LifeTechnologies) and extracted gel fractions were subjected to in-gel 23 
tryptic digestion. Protein bands were distained with 50% (v/v) acetonitrile, reduced with 10 mM 24 
DTT, alkylated with iodoacetamide 55 mM and digested overnight at 37 °C with 6.7 ng/mL 25 
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trypsin. Digested peptides extraction was performed in a water bath sonifier with alternate 1 
100% acetonitrile and 5% formic acid incubations. Analysis of digested peptides was performed 2 
on an ekspert™ NanoLC 425 cHiPLC® coupled to a TripleTOF 6600 with a NanoSpray® III 3 
ion source (Sciex). Reversed-phase separation was performed in a trap-elute mode using a 4 
ChromXP C18 column (75 µm x 15 cm, 3 µm, 120 Å, Sciex) and a ChromXP C18 trap column 5 
(200 µm x 0.5 mm, 3 µm, 120 Å, Sciex). The flow-rate was 300nl/min and the gradient was as 6 
follows: 0-1 min, 95% A (0.1% formic acid in water, fisher); 1-91 min, 5-30% B (0.1% formic 7 
acid in acetonitrile, fisher); 91-93 min, 30-80% B; 93-108 min, 80% B; 108-110 min, 80-5% 8 
B; 110-127 min, 5% B. Electrospray was achieved using an uncoated fused-silica PicoTip™ 9 
emitter (360 µm O.D., 20 µm I.D., 10 ± 1.0 µm tip I.D., New Objective, Oullins, France), with 10 
the following source parameters: 15 GS1, 0 GS2, 30 CUR, 2.4 keV ISVF and 100 ⁰C IHT. An 11 
information dependent acquisition (IDA) method was set with a TOF-MS survey scan of 400-12 
2000 m/z. The 50 most intense precursors were selected for subsequent fragmentation and the 13 
MS/MS were acquired in high sensitivity mode. 14 
The spectra were processed and analyzed using ProteinPilot™ software, with the 15 
Paragon search engine (version 5.0, Sciex). The data dictionary and the parameter translation 16 
files were modified to incorporate the methacrylic anhydride modification in primary amines 17 
(5% probability), with preference for lysine residues (49% probability). A database was 18 
retrieved from UniProt (Swissprot, March 2017 version) and a Homo sapiens restriction was 19 
used. TripleTOF 6600 was selected as the Instrument used and Gel-based ID as a special factor. 20 
The ID focus was on biological modifications and Amino acid substitutions. The search effort 21 
was set as thorough and an FDR analysis was performed. Only the proteins with Unused Protein 22 
Score above 1.3 and 95% confidence were considered. 23 
 24 
2.3.Hydrogel formation 25 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
6 
 
Lyophilized PLMA was dissolved in a solution of 0.5% (w/v) 2-hydroxy-4’-(2-1 
hydroxyethoxy)-2-methylpropiophenone (Sigma-Aldrich, Germany) in PBS (Thermo Fischer 2 
Scientific, USA) to final concentrations of 10%, 15% or 20% (w/v) of PLMA. Hydrogels were 3 
made by pipetting the polymer solution to polydimethylsiloxane (PDMS) (Dow Corning, USA) 4 
molds with 3.5mm or 6mm diameter followed by UV irradiation (0.95 W/cm2) during 60s. 5 
 6 
2.4.PLMA hydrogels characterization 7 
2.4.1.Structural properties of PLMA hydrogels by Scanning Electron Microscopy 8 
The hydrogels were frozen with liquid nitrogen and then lyophilized. Samples were 9 
sputter-coated with gold and imaged via SEM using Ultra-high Resolution Analytical Scanning 10 
Electron Microscope HR-FESEM Hitachi SU-70 (Hitachi, Tokyo, Japan). SEM images were 11 
analyzed by ImageJ software for pore size measurement.  12 
 13 
2.4.2.Water content 14 
Hydrogel samples of PLMA100 and PLMA300 at 10%, 15% and 20% (w/v) were made 15 
in triplicate and immersed in 5 mL of PBS. Samples were incubated at room temperature during 16 
16 hours. After incubation the wet weight (ww) was measured and samples were frozen and 17 
lyophilized. After lyophilization, dry weight (wd) was measured and compared with the initial 18 
wet weight. The water content was calculated according to the following equation: 19 
Water content (%) =  
ww−wd
ww
× 100 (1) 20 
 21 
2.4.3.Mechanical properties 22 
The mechanical behavior of PLMA hydrogels was characterized on the basis of 23 
compression tests employing a Universal Mechanical Testing Machine Shimadzu MMT-101N 24 
(Shimadzu Scientific Instruments, Kyoto, Japan) equipped with a load cell of 100 N. To this 25 
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end, both unidirectional and cyclic compression assays were performed at room temperature on 1 
fresh-prepared cylindrical hydrogels specimens with a diameter of 3.5 mm and height of 2 mm. 2 
The nominal stress was obtained by dividing the compressive load by the initial (uncompressed) 3 
cross-sectional area of the specimen. The compressive modulus was defined as the slope of the 4 
linear region of the strain/stress curve, corresponding to 0–10% strain. Ultimate stress and 5 
ultimate strain values were taken as the point where failure of the hydrogel occurred. 6 
 7 
2.4.4.Rheological studies 8 
Elastic and viscous moduli of PLMA solutions during the photopolymerization process 9 
were studied by photorheology. Both PLMA100 and PLMA300 solutions at 10%, 15% and 10 
20% (w/v) were used for rheological studies. A Kinexus Lab+ (Malvern Panalytical, UK) 11 
equipped with a UV curing attachment was used to characterize the photocrosslinking kinetics. 12 
The gap setting was fixed as 0.5 mm and light intensity (0.95 W/cm2) was used for the 13 
crosslinking reaction of the precursor. Tests were performed at 25 °C with a frequency of 1.0 14 
Hz and 0.02% of shear strain. 15 
 16 
2.5.In vitro cell culture 17 
2.5.1.Cell culture and encapsulation 18 
The biological performance of PLMA hydrogels was assessed using the L929 Mouse 19 
fibroblast cell line (European Collection of Authenticated Cell Cultures (ECACC)) and human 20 
derived adipose stem cells (hASCs) (ATCC). L929 cells were cultured in Dulbecco's Modified 21 
Eagle's Medium low glucose (Sigma-Aldrich, Germany), supplemented with 10% FBS 22 
(Thermo Fisher Scientific, USA) and 1% antibiotic/antimycotic (Thermo Fisher Scientific, 23 
USA). Cells were used between passages 3 and 25.  hASCs were cultured in Minimum Essential 24 
Alpha Medium (Thermo Fisher Scientific, USA) supplemented with 10% FBS (Thermo Fisher 25 
Scientific, USA) and 1% antibiotic/antimycotic (Thermo Fisher Scientific, USA). hASCs were 26 
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used until passage 5. Cell suspensions were prepared by trypsinization (trypsin/EDTA solution, 1 
Sigma-Aldrich, Germany). The cells were incorporated into the PLMA solutions to a final 2 
density of 2x106 cells/mL in the case of L929 and 3x106 cells/mL for hASCs. The hydrogels 3 
were prepared as described previously in section 2.3 with 6mm diameter. 4 
 5 
2.5.2.Live/Dead assay  6 
At pre-determined time points, hydrogels were incubated in a solution of 2μL of Calcein 7 
AM 4mM solution in DMSO (Thermo Fisher Scientific, USA) and 1μL of Propidium iodide 8 
(PI) 1 mg/mL (Thermo Fisher Scientific, USA) in 1000μL of PBS at 37ºC during 30 minutes. 9 
After washing with PBS, hydrogels were examined using a fluorescence microscope 10 
(Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss, Germany).  11 
 12 
2.5.3.Cell metabolic activity quantification 13 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, USA) (MTS) was 14 
used to quantify the metabolic activity. After each time point, hydrogels were washed with PBS 15 
and incubated in a solution of MTS reagent diluted in PBS following manufacturer instructions. 16 
Samples were then incubated overnight at 37ºC, protected from light. The quantification was 17 
achieved by measuring absorbance at 490nm (Microplate Reader - Synergy HTX with 18 
luminescence, fluorescence and absorbance, Biotek, USA). Triplicates were made for each 19 
sample and per culturing time. 20 
 21 
2.5.4.Cell proliferation by DNA quantification 22 
DNA quantification was performed using a Quant-iT PicoGreen dsDNA kit (Thermo 23 
Fisher Scientific, USA). Briefly, at pre-determined time-points hydrogels were washed with 24 
PBS, incubated in sterile deionized water and frozen at -80ºC. In order to induce disruption of 25 
the cells encapsulated in the hydrogel, the samples were thawed at 37ºC and placed in an 26 
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ultrasounds bath during approximately 30 minutes. DNA standards were prepared with 1 
concentrations ranging between 0 and 2 g/mL. The plate was incubated for 10 min in the dark 2 
and fluorescence was measured using an excitation wavelength of 480 nm and an emission 3 
wavelength of 528 nm (Microplate Reader - Synergy HTX with luminescence, fluorescence 4 
and absorbance, Biotek, USA). Triplicates were made for each sample and per culturing time. 5 
 6 
2.5.5.Cell morphology analysis 7 
DAPI/Phalloidin staining was made in order to access the morphology of encapsulated 8 
cells. At pre-determined time-points hydrogels were washed with PBS and fixed with a 4% 9 
formaldehyde (Sigma-Aldrich, Germany) solution during at least 2 hours. For DAPI/Phalloidin 10 
staining, a phalloidin solution (Flash Phalloidin™ Red 594, 300U, Biolegend, USA) was 11 
diluted 1:40 PBS and hydrogels were incubated at room temperature in phalloidin solution 12 
during 45 min. After washing with PBS a DAPI (4',6-diamidino-2-phenylindole 13 
dihydrochloride, Thermo Fisher Scientific, USA) solution was diluted in 1:1000 PBS and 14 
hydrogels were incubated during 5 minutes in this solution at room temperature. After washing 15 
with PBS, hydrogels were examined using a fluorescence microscope (Fluorescence 16 
Microscope Zeiss, Axio Imager 2, Zeiss, Germany). 17 
 18 
2.5.6.Immunocytochemistry 19 
hASCs were encapsulated in PLMA hydrogels and cultured during 7 days as described 20 
in 2.5.1. After 7 days of culture hydrogels were washed with PBS and fixed with a 4% 21 
formaldehyde (Sigma-Aldrich, Germany) solution during at least 2 hours. Following fixation, 22 
hydrogels were washed with PBS and permeabilized with 0.5% Triton X-100 BioXtra (Sigma-23 
Aldrich, Germany) in PBS during 30 minutes. Then hydrogels were washed with PBS and 24 
blocked with 0.5% FBS (Thermo Fisher Scientific, USA) in PBS during 1 hour. Alexa Fluor® 25 
647 anti-human CD90 (Thy1) Antibody (BioLegend, San Diego, CA) and PE anti-human CD73 26 
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(Ecto-5'-nucleotidase) Antibody (BioLegend, San Diego, CA) were diluted in 0.5% FBS in PBS 1 
and incubated overnight at 4ºC. After washing with PBS a DAPI (4',6-diamidino-2-2 
phenylindole dihydrochloride, Thermo Fisher Scientific, USA) solution was diluted in 1:1000 3 
PBS and hydrogels were incubated during 5 minutes in this solution at room temperature to 4 
fluorescently label the nuclei. After washing with PBS, hydrogels were examined using a 5 
fluorescence microscope (Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss, Germany). 6 
 7 
2.6.Quantification of protein and GFs release from PLMA hydrogels 8 
For the protein release assays, six samples of each PLMA100 at 10% and 15% (w/v) 9 
were made. Samples were added to falcons with 5 mL of PBS (Thermo Fischer Scientific, USA). 10 
The samples were incubated in a bath at 37ºC with constant agitation (60 rpm). At each time 11 
point, an aliquot of 600 µL was taken from each sample and 600 µL of fresh PBS added. 12 
Collected samples were stored at -20ºC. Total protein quantification was performed with Micro 13 
BCA Protein Assay Kit (Thermo Fisher Scientific, USA). ELISA quantification of fibrinogen 14 
(Human Fibrinogen ELISA Kit, abcam, UK) and VEGF (VEGF Human ELISA Kit, 15 
InvitrogenTM, ThermoFisher Scientific, USA) was also performed.  16 
 17 
2.7.Fabrication of PLMA microstructures  18 
Lyophilized PLMA100 was dissolved with 0.5% (w/v) 2-hydroxy-4’-(2-19 
hydroxyethoxy)-2-methylpropiophenone (Sigma-Aldrich, Germany) in PBS (Sigma-Aldrich, 20 
Germany) to a final concentration of 15% (w/v). 50µL of this solution were poured onto a glass 21 
coverslip. Then, a photomask was brought into contact with the solution and gently pressed. 22 
The photomask was exposed to UV irradiation (0.95 kW/cm2) during 60s. The photomask was 23 
then removed from the glass. PLMA microstructures were labeled by incubation in 1mL of 24 
Fluorescein 5(6)-isothiocyanate (FITC) (1 µg/mL) (Sigma-Aldrich, Germany) in PBS (Sigma-25 
Aldrich, Germany) and Rhodamine B isothiocyanate (1 µg/mL) (Sigma-Aldrich, Germany) in 26 
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PBS (Sigma-Aldrich, Germany). After 10 minutes of incubation the microstructures were 1 
washed with PBS (Sigma-Aldrich, Germany) and visualized using a fluorescence microscope 2 
(Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss).  3 
 4 
2.8.Statistical analysis 5 
All data were subjected to statistical analysis and were reported as a mean ± standard 6 
deviation. Statistical differences between the analyzed groups were determine by two-tailed 7 
unpaired t test where P < 0.01 were considered as significant. All statistical analysis was 8 
performed using GraphPad Prism software.  9 
 10 
3.Results and discussion 11 
3.1.Synthesis and PLMA characterization 12 
Human platelets are an important autologous source of multiple proteins, GFs and 13 
cytokines that can be extracted by platelet lysis.[27] In this study, photopolymerizable Platelet 14 
lysates (PL) based hydrogels with tunable physical properties that can be used for cell 15 
encapsulation or as substrates for two-dimensional (2D) cell culture were synthesized for the 16 
first time.  Methacryloyl platelet lysates (PLMA) were synthesized by reaction of PL with MA. 17 
Based on previously published works on the modification of gelatin and tropoelastin with 18 
methacrylate groups[7,28–32], we developed a protocol for the synthesis of PL proteins modified 19 
with methacryloyl groups. Proteins present in PL have amino and hydroxyl groups susceptible 20 
to react with methacrylic anhydride – see figure 1A. Different degrees of methacrylation could 21 
be obtained by varying the molar ratio of MA to PL concentration. In this work two degrees of 22 
modification were synthesized: low degree of modification (PLMA100) and high degree of 23 
modification (PLMA300).  The degree of conversion with MA groups (i.e. degree of 24 
methacrylation) in biopolymers has conventionally been determined using 1H NMR 25 
spectroscopy. Despite the complex variety of proteins and GFs in PL, 1H NMR analysis to 26 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
12 
 
PLMA confirmed the methacrylation of PL by the appearance of distinctive peaks in the double 1 
bound region (δ 5.2 – 5.6 ppm) (figure 1B) and a sharp peak that corresponds to the -CH3 of 2 
the methacrylate groups (δ ≈ 2 ppm) (figure 1B) on the modified PL spectra.  3 
 4 
 5 
Figure 1. A) Methacrylate and methacrylamide groups inserted after reaction of PL with 6 
methacrylic anhydride. B) 1H NMR spectra of PL, PLMA100 and PLMA300 with distinctive 7 
peaks characteristics of methacrylate groups: double bound methacrylate (1) and -CH3 of 8 
methacrylate group (2). 9 
 10 
For a more accurate analysis of the protein modifications, mass spectrometry was also 11 
performed. Platelets contain more than 1100 different proteins, with numerous post-12 
translational modifications, resulting in over 1500 protein-based bioactive factors.[33] Table 1 13 
summarizes the main components found in the original PL and PLMA samples starting from 14 
the most abundant protein (N=1). Results demonstrated that the main components of PL did not 15 
significantly change upon conjugation of proteins with methacryloyl groups. Results also show 16 
that human serum albumin is the most abundant protein in both PL and PLMA.  17 
 18 
 PL PLMA100 PLMA300  
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N Protein Protein  Protein 
1 Serum albumin  Serum albumin  Serum albumin  
2 Apolipoprotein B-100  Serotransferrin  Complement C3  
3 Complement C3  Complement C3  Serotransferrin  
4 α2 macroglobulin  α2 macroglobulin  α2 macroglobulin  
5 Serotransferrin  Keratin type II cytoskeletal 1  Apolipoprotein B-100  
6 Complement C4-B  Apolipoprotein B-100  Keratin, type II cytoskeletal 1  
7 Keratin type I cytoskeletal 10  Keratin type I cytoskeletal 9 α1 antitrypsin  
8 Immunoglobulin γ1 heavy chain  Apolipoprotein A-I Keratin type I cytoskeletal 10  
9 Keratin type II cytoskeletal 1  Keratin type I cytoskeletal 10  Haptoglobin 
10 Apolipoprotein A-I Haptoglobin Apolipoprotein A-I 
11 α1 antitrypsin  Immunoglobulin γ1 heavy chain  Complement C4-B  
12 Haptoglobin α1 antitrypsin  Immunoglobulin γ1 heavy chain  
13 
Keratin type II cytoskeletal 2 
epidermal  
Keratin type II cytoskeletal 2 
epidermal  
Keratin type II cytoskeletal 2 
epidermal  
14 Ceruloplasmin Immunoglobulin heavy constant mu  Ceruloplasmin 
15 Keratin type I cytoskeletal 9 Immunoglobulin heavy constant α1  Keratin type I cytoskeletal 9 
16 Apolipoprotein A-IV  Ceruloplasmin Immunoglobulin heavy constant um 
17 Hemopexin  Hemopexin  Hemopexin  
18 Immunoglobulin mu heavy chain  
Inter α-trypsin inhibitor heavy chain 
H4  
α1-B-glycoprotein  
19 Complement factor B  Keratin type II cytoskeletal 5  Immunoglobulin heavy constant α1  
20 Complement factor H  Antithrombin-III  
Inter α-trypsin inhibitor heavy chain 
H4  
21 
Immunoglobulin heavy constant 
alpha 1  
Keratin, type I cytoskeletal 14  Actin, cytoplasmic 2  
22 Vitamin D-binding protein  α1-B-glycoprotein  Immunoglobulin kappa light chain  
23 Complement C5  Actin cytoplasmic 2  Transthyretin  
24 Actin cytoplasmic 2  Immunoglobulin kappa light chain  Apolipoprotein A-IV  
25 α1-B-glycoprotein  Immunoglobulin heavy constant γ2  
Inter-α-trypsin inhibitor heavy chain 
H2 
26 Fibrinogen γ chain  Complement factor B  Antithrombin-III  
27 Fibrinogen α chain  α1-acid glycoprotein 1  Vitamin D-binding protein  
28 
Inter-α-trypsin inhibitor heavy chain 
H4  
Vitronectin  α1-antichymotrypsin  
29 
Inter-α-trypsin inhibitor heavy chain 
H2 
Inter-α-trypsin inhibitor heavy chain 
H1  
Complement factor B  
30 Immunoglobulin kappa light chain  Kininogen-1  Plasma protease C1 inhibitor 
31 α1-antichymotrypsin  Fibrinogen γ chain  Apolipoprotein E  
32 Antithrombin-III  α1-antichymotrypsin  Immunoglobulin heavy constant γ2 
33 Prothrombin  Complement C4-B  Vitronectin  
34 Apolipoprotein E  Apolipoprotein A-IV  Fibrinogen γ chain  
35 Fibrinogen β chain  Angiotensinogen  Angiotensinogen 
Table 1.  Main components found in PL, PLMA100 and PLMA300 by mass spectrometry 1 
analysis, listed according to their relative abundance. 2 
 3 
Based on the mass spectrometry results showing the main proteins found in PL, it was 4 
calculated the relative peptide content (%) compared with the total peptides found in PL. Figure 5 
2 represents the relative percent of peptides found for each protein compared with the total 6 
amount of peptides.  7 
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 1 
 2 
Figure 2. Relative percent of peptides found in original PL for each main protein compared 3 
with the total amount of found peptides. 4 
 5 
The total peptide sequences per formulation (PLMA100 and PLMA300) and the amount 6 
of modified peptide sequences was obtained by mass spectrometry. The degree of modification 7 
was then estimated by dividing the amount of modified peptide sequences by the total peptide 8 
sequences. As it was expected, mass spectrometry results for PLMA100 reveals less modified 9 
peptides with methacryloyl groups than in PLMA300 (table 2) and most of these modification 10 
sites occur in serum albumin peptides (figure 3). Mass spectroscopy results reveal that 11 
modification occurs in different residues but mainly in lysine (K) and glutamine (Q) residues, 12 
as it was previously reported for the modification of gelatin and tropoelastin with this type of 13 
chemical conjugation.[31]  14 
 15 
Sample 
Total peptide 
sequences 
Modified peptide 
sequences 
Degree of 
modification 
PLMA100 2410 346 14% 
PLMA300 3391 846 25% 
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 1 
Table 2. Mass spectrometry results for total number of identified peptides and also the number 2 
of modified peptides found. 3 
 4 
 5 
Figure 3. Modified peptides for each protein found in PLMA100 and PLMA300. 6 
 7 
 8 
 9 
 10 
3.2.Hydrogel formation  11 
Hydrogels were easily and rapidly formed by photopolymerization upon exposure of 12 
PLMA solution to UV irradiation. The obtained PLMA formulation is water soluble and its low 13 
viscosity allow the preparation of PLMA solutions up to 20% (w/v). This characteristic is 14 
especially important in injectable hydrogels as this way its application is easier and requires 15 
minimally invasive procedures. Another important characteristic of these hydrogels is the fact 16 
that the total crosslinking occurs in 30s to 60s of UV exposure at quite low intensity, 0.95 17 
W/cm2. Figure 4 shows PLMA hydrogels for each modification degree at 10%, 15% and 20% 18 
(w/v).  19 
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 1 
 2 
Figure 4. Photocrosslinked PLMA hydrogels formed from PLMA100 and PLMA300 at 10%, 3 
15% and 20% (w/v).  4 
 5 
3.3.Characterization of PLMA hydrogels  6 
3.3.1.Structural properties of PLMA hydrogels 7 
Hydrogels porosity influences nutrient flux throughout the matrix and is related with 8 
hydrogel swelling and mechanical properties.[34] Small molecular porosity is correlated with 9 
lower swelling ratio and higher modulus.[34–36] Molecular porosity and mechanical properties 10 
of hydrogels are important characteristics that have to be taken into account due to its influence 11 
in cell behavior. Penetration of cells into hydrogels, as well as migration, proliferation and 12 
exchange of oxygen, nutrients and waste materials are processes influenced by hydrogel 13 
stiffness.[37,38] In order to explore PLMA hydrogels microstructure, SEM analysis of lyophilized 14 
PLMA gels was performed. These structures have a porous network influenced by PLMA 15 
concentration and also modification degree, as showed in figure 5A-B. Results also show that 16 
PLMA hydrogels have a heterogenic structure with respect to porosity with a slight decrease in 17 
pore size with the increase in PLMA concentration for PLMA100. The diminution in pore size 18 
with the increase of PLMA concentration is more significant for PLMA300, from an average 19 
pore size at PLMA300 10% (w/v) of ~10 µm up to ~5 µm at PLMA300 20% (w/v).  20 
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 1 
 2 
Figure 5. (A) Representative cross-section SEM images of PLMA100 and PLMA300 3 
hydrogels. (B) Pore size values obtained for PLMA100 and PLMA300. (C) Water content for 4 
PLMA100 and PLMA300 hydrogels. All studies were performed for PLMA100 and PLMA300 5 
hydrogels at 10%, 15% and 20% (w/v). Statistical analysis through two-tailed unpaired t test 6 
showed significant differences (*P < 0.01) between the analyzed groups. 7 
 8 
The porosity of PLMA hydrogels is not very different from other protein based 9 
hydrogels like gelatin methacryloyl and it can be tuned by changing some hydrogel fabrication 10 
parameters[37], which does not occur for other hydrogels like tropoelastin methacrylate based 11 
hydrogels where pore size is not very different for each low modification degree 12 
concentration.[32] 13 
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The water content of PLMA hydrogels was also evaluated. Results shown that this 1 
parameter is not significantly influenced by the degree of modification or PLMA concentration. 2 
In general, PLMA hydrogels have more than 90% of water content (Figure 5C). 3 
 4 
3.3.2.Mechanical and rheological characterization 5 
PL based gels formed upon activation of PL concentrates with calcium and thrombin 6 
have been used as materials for cell culture.[39,40] Nevertheless, these hydrogels typically present 7 
poor mechanical properties and are difficult to handle. Moreover, they tend to degrade fast in 8 
vitro, unless some antifibrinolytic agent is used in order to slow down the degradation 9 
process.[41] On the other side, animal based materials such as collagen and the mixture of 10 
proteins derived from the EHS tumor, widely used as cell culture matrices have issues with 11 
handling and own potential immunogenicity. To overcome these limitations, the human based 12 
hydrogels here proposed may be easily tuned to present enhanced stability and well controlled 13 
mechanical properties.  14 
Rheological measurements were performed for PLMA100 and PLMA300 at 10%, 15% 15 
and 20% (w/v) to study the photopolymerization process of PLMA materials – see figure 6. 16 
The storage modulus increases with the increase in concentration or degree of modification – 17 
see figure 6A and 6B. Figure 6C presented the time needed to achieve an hydrogel with a 18 
modulus approximately half of the final (t1/2). For each condition, t1/2 decreases with an increase 19 
in PLMA concentration or degree of modification, possibly due to the higher availability of 20 
double bounds to induce crosslinking. tan δ gives the ratio between the storage modulus (G’) 21 
and the loss modulus (G’’). These values, between 0.05 and 0.2, clearly demonstrate the 22 
viscoelastic nature of the resulting hydrogels. tan δ increases with increasing concentration and 23 
degree of modification, therefore increasing the damping capability of the hydrogel. 24 
 25 
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 1 
Figure 6. Representative curves for storage modulus (G’) for PLMA100 (A) and PLMA300 2 
(B). (C) t1/2 and tan δ for PLMA100 and PLMA300. All studies were performed for PLMA100 3 
and PLMA300 hydrogels at 10%, 15% and 20% (w/v). Statistical analysis through two-tailed 4 
unpaired t test showed significant differences (*P < 0.01) between the analyzed groups. 5 
 6 
 7 
We also tested PLMA hydrogels mechanical properties and how they change by varying 8 
PLMA modification degree and concentration. As for rheological measurements, compressive 9 
mechanical tests were performed in hydrogels made from PLMA100 and PLMA300 at 10%, 10 
15% and 20% (w/v). Figure 7A shows the compressive stress-strain results of PLMA hydrogels. 11 
The data shown in figure 7B shows how Young’s modulus increases with the increase in the 12 
PLMA concentration. Likewise, an increase in the degree of modification of PL, corresponds 13 
to an increase in stiffness for the same concentration of polymer.  Young’s modulus of 14 
PLMA100 is lower for all concentration tested when compared with the same concentrations 15 
of PLMA300 hydrogels. Figure 7C shows the ultimate strain (%) for PLMA hydrogels and the 16 
influence of polymer concentration and degree of modification on these values. The ultimate 17 
strain is higher in PLMA at lower concentration (10% (w/v)). Comparing data obtained for both 18 
degrees of modification the ultimate strain is higher in PLMA100 hydrogels than in PLMA300. 19 
PLMA300 hydrogels have less resistance to fracture compared to PLMA100. This may be due 20 
to the higher degree of methacrylation, which increases the crosslinking density of hydrogels 21 
and also its stiffness.[35] Figure 7D shows the ultimate stress for each concentration of two 22 
different modification degrees. An increase in the ultimate stress from the 10% (w/v) to 20% 23 
(w/v) hydrogels is evident. It is important to point out that PLMA hydrogels are formed rapidly 24 
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within 30 - 60 seconds upon UV irradiation, which is shorter than the typical time (~ 20min - 1 
1h) required to crosslink PRP-based gels with calcium and thrombin.[42] 2 
 3 
 4 
  5 
Figure 7. (A) Representative compressive stress-strain curves for PLMA100 and PLMA300 6 
hydrogels. (B) Young's modulus, (C) ultimate strain and (D) ultimate stress results for 7 
PLMA100 and PLMA300. All studies were performed for PLMA100 and PLMA300 hydrogels 8 
at 10%, 15% and 20% (w/v). Statistical analysis through two-tailed unpaired t test showed 9 
significant differences (*P < 0.01) between the analyzed groups (#, significantly different from 10 
all the others on the left). 11 
 12 
 3D cell culture platforms such as hydrogels have to provide ideal features to support cell 13 
adhesion and proliferation, this way mimicking the in vivo extracellular 14 
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microenvironment.[34,43,44] In particular, the mechanical properties play a key role in the in vitro 1 
integrity of the hydrogel and in cellular mechanotransduction, this way affecting cellular 2 
spreading, migration and also differentiation.[45] PLMA hydrogels have unique structural 3 
properties that allow them to behave as a viscoelastic solid with improved mechanical 4 
properties compared to PRP based gels so far reported.[42] The Young’s modulus of the herein 5 
reported hydrogels may be tuned in the range of 0.5 – 20 kPa. Therefore, the developed PLMA 6 
hydrogels can be used to mimic some native tissues with known stiffness between these 7 
Young’s modulus values such as: brain tissue (elasticity 0.1-1 kPa)[43,46] and striated muscle 8 
(elasticity 8-17 kPa).[47]  9 
  10 
3.4.In vitro cell culture studies 11 
L929 mouse fibroblasts were used for a first screening of the biological performance of 12 
the PLMA hydrogels. Cells encapsulated in PLMA100 hydrogels at 10% (w/v) were cultured 13 
during 7 days and at determined time points, namely 1, 3 and 7 days, analysis to cell 14 
morphology, viability and proliferation was performed. Figure 8A shows that cells are well 15 
distributed within the hydrogel, exhibiting high viability and elongated morphology at day 1 16 
and day 7. DAPI/Phalloidin staining was also performed at days 3 and 7 in order to evaluate 17 
cell morphology inside the PLMA hydrogels (figure 8B-C). It is perfectly clear that L929 cells 18 
adhered, spread and proliferated within the PLMA hydrogel. 19 
 In a second assay, hASCs were used in order to test the potential of PLMA hydrogels 20 
to support the culture of human derived stem cells. In a first approach, hydrogels made of 21 
PLMA100 at 10% (w/v) hydrogels were used for hASCs encapsulation likewise for L929 22 
culture. However, the results revealed that these hydrogels do not properly promote hASCs 23 
adhesion and proliferation. Based on literature reports that suggest stiffer hydrogels for 24 
increased hASCs adhesion and proliferation[48,49], PLMA100 hydrogels at a 15% (w/v) 25 
concentration were tested. Live/Dead assay reveal that PLMA hydrogels greatly support cell 26 
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viability up to 7 days in culture (figure 8A). Cell morphology was assessed by DAPI/Phalloidin 1 
staining at 3 and 7 days of culture (Figure 8B-C). After 3 days in culture, cells readily elongated 2 
in PLMA hydrogels and after 7 days in culture cells are perfectly elongated and migrated, 3 
forming interconnected networks with neighboring cells. Immunocytochemistry analysis of 4 
hASCs at 7 days of cell culture with stem cell specific biomarkers (CD90 and CD73) show no 5 
evidence of differentiation of hASCs encapsulated in PLMA hydrogels. 6 
 7 
 8 
 9 
Figure 8. Representative fluorescence images for: (A) L929 encapsulated in PLMA100 10% 10 
(w/v) and hASCs encapsulated in PLMA100 15% (w/v) live/dead at 1 and 7 days of culture in. 11 
(B) and (C) L929 and hASCs DAPI/Phalloidin staining at 3 and 7 days of cell culture. (D) 12 
Immunocytochemistry images of hASCs with CD90/DAPI and CD73/DAPI at 7 days of cell 13 
culture. DNA (E) and MTS (F) results for L929 and hASCs at 1 day, 3 and 7 days of cell culture. 14 
Statistical analysis through two-tailed unpaired t test showed significant differences (*P < 0.01) 15 
between the analyzed groups. 16 
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 1 
Cell proliferation and cell viability assays were performed by DNA quantification 2 
(Figure 8D) and MTS assay (Figure 8E), respectively. L929 as well as hASCs are able to 3 
proliferate inside PLMA hydrogels as it can be seen by the increasing in DNA content and also 4 
by the results for metabolic activity analysis. These results are in agreement with previously 5 
described results for live/dead assay and DAPI/Phalloidin staining (figure 8A, 8B and 8C), 6 
which demonstrated cell spreading and proliferation within PLMA hydrogels. Cells maintain 7 
their viability for at least 7 days and are able to proliferate inside the hydrogels.  8 
Depending on the cell type, a specific stiffness of PLMA hydrogels may be required, 9 
this is easily adjusted by varying degree of modification or PLMA precursor concentration. For 10 
example, hASCs adhesion was poor on 10% (w/v) PLMA100 hydrogels, when the same cells 11 
were encapsulated within PLMA100 15%, they rapidly adhere and spread within the hydrogels.  12 
Cell migration through ECM is critical in a variety of physiologic and pathophysiologic 13 
situations. Here we propose proteolytically degradable human ECM derived hydrogels as a 3D 14 
cell culture platform. Such biodegradable and bioresponsive hydrogels are therefore promising 15 
materials that can be used for 3D cell culture, in particular to engineer human microtissues or 16 
for the development of humanized in vitro disease models. 17 
 18 
3.5.Microfabrication of PLMA based hydrogels 19 
Photopolymerizable hydrogels permit to fix the shape of the solution precursor using 20 
light. Microfabricated structures of PLMA hydrogels were obtain by photopolymerization of 21 
PLMA100 15% (w/v) solution using a photomask (figure 9A). PLMA was processed to create 22 
microstructures with multiple geometries that may be further assembled (figure 9B). These 23 
results support the idea that PLMA hydrogels can be manipulated according to user-defined 3D 24 
microstructures in cell-laden microgels and eventually assembled into larger structures to 25 
mimic the tissue hierarchical organization, using bottom-up tissue engineering strategies.[50] 26 
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 1 
Figure 9. (A) Procedure to generate microgels with higher tuned geometry and size. (B) 2 
Representative fluorescence images for: (1) PLMA microgels labeled with FITC; (2) PLMA 3 
microgels labeled with rhodamine B isothiocyanate; (3) PLMA microgels in suspension after 4 
detachment from the glass slide.   5 
 6 
3.6.Release of bioactive molecules from PLMA hydrogels 7 
PLMA hydrogels here described are a pool of proteins, GFs and other molecules that 8 
are essential for cell adhesion, growth and proliferation. We predicted that a fraction of this 9 
complex mixture of proteins will be loosely bounded to the hydrogel after the photocrosslinking 10 
step. For this reason, protein and GFs release assays were performed in order to identify the 11 
release profile from PLMA hydrogels. Figure 10A shows the total protein release profile from 12 
the gels used for in vitro cell encapsulation assays, PLMA100 at 10% and 15% (w/v). Protein 13 
release profile of PLMA hydrogels shows an overall sustained release. In the first 24 hours of 14 
the assay, protein release is quite fast, then between 24h and approximately 240h protein release 15 
is well sustained. It is also important to refer that the hydrogels maintain their shape during the 16 
time release tests were performed. Using an autologous or allogeneic source of GFs instead of 17 
recombinant GFs, which are very expensive and have a short half-life, has already been 18 
proposed.[51–53] PLMA hydrogels are a pool of human GFs and they can be potentially used as 19 
a platform for the release of autologous or allogeneic GFs and bioactive proteins involved in 20 
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cell recruitment, growth and proliferation processes. The vascular endothelial growth factor 1 
(VEGF) is an inducer of angiogenesis that has been long recognized as an important and 2 
necessary step during tissue repair.  3 
On the other hand, fibrinogen has been recognized as a main component in PRP and is 4 
a key element in the previous reported PRP based gels. Thus, ELISA assay was performed to 5 
investigate the release profile of both VEGF and fibrinogen from the PLMA hydrogels. As well 6 
as in total quantification, the release of fibrinogen and VEGF occurs in a sustained manner, as 7 
shown in figure 10B. Typically VEGF concentrations of 5, 10 or 20 ng/mL induced a 2-2.5-8 
fold increase in proliferation and migration of endothelial cells in comparison with no VEGF. 9 
The amount of VEGF released from the hydrogels is quite below these values, further studies 10 
will be performed to evaluate the bioactivity of immobilized VEGF within the hydrogel and its 11 
influence in endothelial cell proliferation and migration. The low amount of fibrinogen released 12 
from the hydrogel, suggest that this protein is a key structural component of the PLMA 13 
structures and covalently bonded to the hydrogel network.  14 
 15 
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 1 
Figure 10. Total protein release quantification (A) and ELISA quantification of fibrinogen and VEGF (B) 2 
for PLMA100 10% and 15% (w/v). 3 
 4 
 5 
 6 
4.Conclusion 7 
PRP and PL are attractive sources of GFs that have been widely studied for TE 8 
applications. Previous studies found in the literature concerning the use of hydrogels based on 9 
PRP, mostly report the activation with thrombin and crosslinking with calcium. Despite the 10 
potential of those systems, the limited mechanical properties, and low stability in vitro results 11 
in an ineffective strategy. Herein we reported, for the first time, a direct modification of PL 12 
proteins with a photoresponsive group. Such modification allow the production of PL derived 13 
photopolymerized hydrogels with tunable mechanical and biochemical properties. The PLMA 14 
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based hydrogels here proposed not only have increased mechanical properties but also higher 1 
stability in vitro when compared to PRP/PL based reported materials. PLMA based hydrogels 2 
support the adhesion and proliferation of encapsulated cells. Our results suggest that such type 3 
of gels may be an alternative to collagen and proteins derived from the Engelbreth-Holm- EHS 4 
tumor, the gold standards to provide 3D cell cultures for a wide range of cell types. A foremost 5 
advantage of PLMA based gels is their human origin, following the current animal-free 6 
approaches and autologous or allogenic strategies for cell culture and biomedical applications. 7 
Recognizing the unprecedented potential of the PLMA gels to support 3D cell culture, we 8 
hypothesize that PLMA based gels may be used as cell culture platforms avoiding the use of 9 
animal derived supplements.  10 
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